These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21329419)

  • 21. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F; Karagoz C; Posaci C; Saatli B; Uysal D; Secil M; Akdeniz B
    Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).
    Bilgir O; Kebapcilar L; Taner C; Bilgir F; Kebapcilar A; Bozkaya G; Yildiz Y; Yuksel A; Sari I
    Intern Med; 2009; 48(14):1193-9. PubMed ID: 19602786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
    Franks S; Layton A; Glasier A
    Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.
    Charitidou C; Farmakiotis D; Zournatzi V; Pidonia I; Pegiou T; Karamanis N; Hatzistilianou M; Katsikis I; Panidis D
    Atherosclerosis; 2008 Feb; 196(2):958-65. PubMed ID: 17418849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.
    Makedos A; Goulis DG; Papanikolaou A; Panidis D
    Angiology; 2010 Aug; 61(6):595-601. PubMed ID: 20395229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction.
    Pepene CE
    Gynecol Endocrinol; 2012 May; 28(5):370-4. PubMed ID: 22456311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
    Kebapcilar L; Kebapcilar AG; Bilgir O; Taner CE; Bozkaya G; Yildiz Y; Sari I
    Gynecol Endocrinol; 2011 Feb; 27(2):91-5. PubMed ID: 20528207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM; Ghosh M; Basu R
    J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
    Sorensen MB; Franks S; Robertson C; Pennell DJ; Collins P
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):655-9. PubMed ID: 17054469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.